Showing 9181-9190 of 20379 results for "".
- Produce Prescription Subsidy in Diabetes: Pragmatic Trial Resultshttps://reachmd.com/news/produce-prescription-subsidy-in-diabetes-pragmatic-trial-results/2487092/Key Takeaways At 12 months, the produce prescription subsidy was not associated with better glycemic outcomes than usual care. No between-group differences were reported in emergency department visits, blood pressure, body mass index, or inpatient visi
- Revolutionizing Pediatric Diabetes Care: The Role of Tirzepatidehttps://reachmd.com/news/revolutionizing-pediatric-diabetes-care-the-role-of-tirzepatide/2483463/As incretin-based therapies advance, clinicians are weighing early pediatric data on tirzepatide against established standards of care that prioritize metformin and insulin in youth, with limited use of GLP-1 receptor agonists. Within that context, tirzepatide—an emerging option in
- Unlocking New Pathways: Cabergoline’s Role in Diabetes Managementhttps://reachmd.com/news/unlocking-new-pathways-cabergolines-role-in-diabetes-management/2482990/Central to the scientific interest in cabergoline is the hypothesis that it may influence glucose control via dopamine D2-like receptor agonism, a concept supported by preliminary evidence discussed in a mechanistic review. Building on that framework,
- Cardiovascular and Safety Signals After GLP‑1 Discontinuation: Register Evidencehttps://reachmd.com/news/cardiovascular-and-safety-signals-after-glp1-discontinuation-register-evidence/2486323/A large register-based analysis of U.S. veterans with type 2 diabetes reported that stopping or interrupting GLP-1 receptor agonist therapy was associated with higher rates of major adver
- Navigating the Pathways of Glucose to Enhance Metabolic Healthhttps://reachmd.com/news/navigating-the-pathways-of-glucose-to-enhance-metabolic-health/2483007/Glucose transporters continue to influence the regulation of insulin secretion and broader metabolic processes. Their relevance in managing type 2 Diabetes and endocrine disorders is well-established. The mechanism of glucose transporters involves isoforms such as GLUT2 and GLUT4 fac
- Merging Nutritional and Molecular Strategies in Metabolic Disorder Managementhttps://reachmd.com/news/merging-nutritional-and-molecular-strategies-in-metabolic-disorder-management/2475157/Clinicians are witnessing the convergence of molecular tracers and nutritional science to tackle the complexities of metabolic disorders, with glucagon isotopes illuminating elusive pancreatic alpha cell behavior in Type 1 diabetes, while nat
- Revolutionizing Chronic Disease Management Through Telemedicine and Physical Activityhttps://reachmd.com/news/revolutionizing-chronic-disease-management-through-telemedicine-and-physical-activity/2471231/The integration of telemedicine and strategic physical activity is transforming how chronic diseases, particularly type 2 diabetes, are managed, offering improved patient outcomes and innovative healthcare solutions. Telemedicine's Role in Chro
- A Breakthrough in Curbing Sugar Cravingshttps://reachmd.com/news/breakthrough-curbing-sugar-cravings/2470891/What's New Researchers have identified a gut bacterium linked to reduced sugar cravings, highlighting potential therapeutic pathways for managing obesity and type 2 diabetes. Significance Understanding the interaction between gut microbes and dietary
- Ozempic and Hair Loss: Exploring the Link and Managing Side Effectshttps://reachmd.com/news/ozempic-and-hair-loss-exploring-the-link-and-managing-side-effects/2468501/Hair loss is emerging as a surprising and concerning side effect among some Ozempic users, sparking questions about the causes and potential solutions. Ozempic, known generically as semaglutide, was originally developed for type 2 diabetes but is increasingly u
- Weight Loss Maintained for 20 Years: Study Reveals Long-Term Effectiveness of Gastric Bypasshttps://reachmd.com/news/weight-loss-maintained-for-20-years-study-reveals-long-term-effectiveness-of-gastric-bypass/2467021/Research from Geisinger Medical Center shows Roux-en-Y gastric bypass surgery holds type 2 diabetes in remission for 15 years and supports sustainable weight loss for 20 years, underscoring its lon